Nachrichten zur Pfizer Inc. Aktie

Pfizer Says Its Biggest Headwinds Are Finally Easing. Does That Change the Story for This Ultra-High-Yield Dividend Stock?

Pfizers rebound is well underway.…

Pfizer Says Its Biggest Headwinds Are Finally Easing. Does That Change the Story for This Ultra-High-Yield Dividend Stock?

Pfizers rebound is well underway.…

Is Pfizer an Excellent Dividend Stock to Buy?

…

2 High-Yield Dividend Stocks to Buy and 1 to Avoid

Id buy Energy Transfer and Verizon stocks, and avoid Pfizer.…

The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux

Prostate cancer awareness spotlights Pfizers Xtandi, Novartis Pluvicto and clinical-stage programs from Candel and Janux.…

IP Group eyes busy second half as Pfizer obesity investment catches the eye

IP Group PLC (LSE:IPO), which backs companies spun out of British universities, said it was entering the second half of…

4 Prostate Cancer Drug Stocks to Watch During Awareness Month

Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.…

How Concerned Should Income Investors Be About Pfizers Dividend?

Pfizer has a huge 6% yield and a payout ratio well over 100%, yet the company is still maintaining the…

How Concerned Should Income Investors Be About Pfizers Dividend?

Pfizer has a huge 6% yield and a payout ratio well over 100%, yet the company is still maintaining the…

Medicus Pharma CEO on SkinJect and Pfizer partnership

Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress across its SkinJect program and a co-development and licensing opportunity with Pfizer,...…

Pfizer Aktie: HSBC erhöht Kursziel - reicht das für das Comeback?

Bad Marienberg (www.aktiencheck.de) - Bei Pfizer Inc. (ISIN: US7170811035, WKN: 852009, Ticker-Symbol: PFE, NYSE-Symbol: PFE) kommt Bewegung in die Bewertung:…

Pfizer Aktie: Bodenbildung nimmt Gestalt an

Düsseldorf (www.aktiencheck.de) - Pfizer-Chartanalyse von HSBC Trinkaus & Burkhardt:Die Analysten von HSBC Trinkaus & Burkhardt nehmen die Aktie von Pfizer…

Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?

PFEs non-COVID growth, oncology pipeline and cost cuts offer a path forward as COVID sales fall and patent losses loom.…

Novartis India inks $132M asset purchase deal with Pfizer for Minipress brands

…

Pfizer (PFE) Up 12.4% Since Last Earnings Report: Can It Continue?

Pfizer (PFE) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…

Pfizers Pipeline Strategy Centers on Obesity and Oncology

PFEs pipeline is taking center stage as berobenatide and next-generation oncology drugs aim to drive growth from 2028 and beyond.…

TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26

By David Bautz, PhDNASDAQ: TNXPREAD THE FULL TNXP RESEARCH REPORTBusiness Update$11.0 Million in Net Revenue for Tonmya® in 2Q26Tonix Pharmaceuticals…

From Padcev to PF-08634404: Pfizers Oncology Growth Push

PFEs oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains.…

The Most Concerning Thing About Pfizers Dividend Isnt What You Think

Pfizers payout ratio is above 100%, but thats not the number you should probably be watching right now.…

PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now?

PFE and BMY both boast strong oncology portfolios, but Pfizers valuation and broader diversification make it the more attractive pick…

Prediction: This Is Where Pfizer Stock Will Be in 2030

Pfizer is facing material patent expirations over the next two years, but that will be over by 2030.…

Pfizer: Still Cheap Valuation Meets A Looming Patent Cliff

…

Valneva outlines $145M-$160M 2026 revenue guidance while Pfizer targets Lyme decisions within 12 months

…

PLX: Elfabrio Estimates Up

By John Vandermosten, CFANYSE: PLXREAD THE FULL PLX RESEARCH REPORTSecond Quarter 2026 Financial and Operational ReviewProtalix BioTherapeutics, Inc. (NYSE: PLX)…

Will Pfizers Non-COVID Portfolio Drive Its Next Phase of Growth?

PFEs non-COVID products are gaining momentum, with launches, acquisitions and a pipeline aimed at driving growth from 2029 onward.…

Valneva Aktie: Borreliose-Impfstoff als großer Wachstumstreiber - Kursziel 12 Dollar

New York (www.aktiencheck.de) - Valneva-Aktienanalyse von TD Cowen:Die Analysten von TD Cowen nehmen die Coverage für die Aktie von Valneva…

Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock

This problem has a solution, and Pfizer is implementing it.…

Pfizers Earnings Have Declined 58% This Year. Is a Dividend Cut Around the Corner?

The stocks 6.4% yield is attractive, but it comes with risk.…

Pfizer Aktie: Milliarden-Abschreibungen und verschärftes Sparprogramm

Frankfurt (www.aktiencheck.de) - Pfizer-Aktienanalyse von XTB:Der US-Pharmagigant Pfizer Inc. (ISIN: US7170811035, WKN: 852009, Ticker-Symbol: PFE, NYSE-Symbol: PFE) hat mit seinen…

Berenberg belässt Pfizer auf Hold - Ziel 25 Dollar

HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Pfizer nach Quartalszahlen auf "Hold" mit einem Kursziel von…

ANALYSE-FLASH: JPMorgan belässt Pfizer auf 'Neutral' - Ziel 28 Dollar

NEW YORK (dpa-AFX) - Die US-Bank JPMorgan hat die Einstufung für Pfizer nach Zahlen zum…

US-Pharmakonzern Pfizer wächst unerwartet stark - Umsatzziel angehoben

NEW YORK (dpa-AFX) - Der US-Pharmakonzern Pfizer blickt nach einem unerwartet starken Wachstum im zweiten…

Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs

Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion…

Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis

Pfizer beat Wall Street estimates for ?second-quarter profit on Tuesday, driven by strong demand for ?its blood thinner, Eliquis.…

Pfizer raises revenue outlook after quarterly earnings top estimates

Pfizer Inc (NYSE:PFE, XETRA:PFE) beat Wall Street expectations for its second-quarter 2026 results and raised the midpoint of its full-year…

Pfizers Stock Has Been a Dud Over the Past 5 Years, but Is It Still Worth Buying for Its 6.9% Yield?

The stocks yield is more than six times the S&P 500 average.…

Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?

Amgen, Pfizer, Eli Lilly, Merck and Novo Nordisk are set to report Q2 results this week after a strong start…

Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock?

There is more to this stock than meets the eye.…

Pfizers Bear Case Is Breaking

…

Pfizer Stock Ahead of Q2 Earnings: To Buy or Not to Buy?

Pfizer heads into Q2 earnings with expectations for growth in key products, COVID headwinds, and guidance updates that could shape…

Schutz vor dem KI-Rücksetzer: Jefferies rät zu Dividenden-Schwergewichten - diese Aktien stechen heraus

Jefferies rät zu Aktien mit niedriger Volatilität und hoher DividendeProcter & Gamble, Pfizer, KeyCorp und Simon Property Group stehen im…

Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.…

Pfizer: Calling The Bottom - The Patent Cliff Is Real, But The Valuation Has Fallen Too Far

…

Pfizers Dividend Yield Looks Almost Too Good. Heres Why Management Isnt Worried.

Pfizer has a 6.8% yield at a time when the markets yield is roughly 1%: Is there something wrong?…

Is Pfizers 7% Dividend Yield Too Good to Be True? Heres the Straight Answer

Income seekers shouldnt give up on the stock yet.…

Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know

In the latest trading session, Pfizer (PFE) closed at $24.75, marking a -1.2% move from the previous day.…

Looking for Cheap Income Stocks? Why Pfizer Belongs on Your Shortlist Right Now

Pfizer is a highly respected drug company facing normal industry headwinds.…

Heres How Pfizers Oncology Growth Story Looks Ahead of Q2 Results

PFEs oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates…

Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?

The pharma giants yield of around 7.1% is more than six times the S&P 500 average.…

CEO Chat with Dr. Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics

NASDAQ: LABTDavid Bautz, PhD: Welcome to our next episode in our CEO Chat series. My name is David Bautz. Im…